Hwail Pharmaceutical Co. Ltd. | Mutual Funds
Mutual Funds that own Hwail Pharmaceutical Co. Ltd.
DFA Emerging Markets Core Equity Portfolio
104,578
0.73%
12,975
0%
04/30/2018
DFA Emerging Markets Small Cap Series
74,710
0.52%
0
0.01%
01/31/2018
Symmetry Moderate Growth Portfolio
8,108
0.06%
97
0%
06/30/2018
Symmetry Growth Portfolio
8,089
0.06%
287
0.01%
06/30/2018
Dimensional Funds ICVC - Emerging Markets Core Equity Fund
5,434
0.04%
0
0%
12/31/2017
DFA TA World (ex-US) Core Equity Portfolio
2,876
0.02%
0
0%
04/30/2018
DFA World (ex-US) Core Equity Portfolio
2,785
0.02%
0
0%
04/30/2018
John Hancock II - Emerging Markets Fund
2,270
0.02%
0
0%
04/30/2018
Symmetry Balanced Portfolio
2,179
0.02%
35
0%
06/30/2018
Symmetry Conservative Portfolio
2,154
0.02%
-61
0%
06/30/2018
| Address |
57 Jeyakgongdan 3-gil
Hwaseong GY 18622
Korea, Republic Of
|
|
Employees
|
- |
| Website |
http://www.hwail.com |
| Updated |
09/14/2018 |
| HWAIL PHARMACEUTICAL Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following businesses: Pharmaceutical Raw Material, Cephalosporin Antibiotic, Functional Health Food Ingredient. Its products include antitussive expectorants, spasmolytic, stomach function modifier, anti-inflammatory and others. |
